Cell and gene therapy represents a cutting-edge approach in the field of biotechnology, offering revolutionary treatments for a wide range of diseases. The rapid evolution of cell and gene therapy holds great potential for transforming healthcare by providing personalized and curative treatments for patients with previously untreatable conditions. This session delves into the complexities and advancements in the production of these innovative therapies. The manufacturing process for cell and gene therapies is highly specialized, requiring stringent quality control measures, sterile environments, and precise techniques to ensure safety and efficacy. As these therapies continue to show promising results in clinical trials, the scalability and cost-effectiveness of manufacturing processes remain key challenges. In this session we will discuss…

• Why Cell and Gene Therapies are representing the next evolutionary step in Bioprocessing
• Which processes can be taken over from the well-proven Biologics playbook?
• Why areas as process understanding and analytics need so much work
• From Process Development to Clinical Manufacturing to Commercial Manufacturing – How can the risks of a partially individualized and expensive manufacturing process be reduced?
• How can quality be assured whilst using disruptive Technologies for producing these materials?
• How robust process are can be assured for commercial production and how processes can be adapted for individualized production